IceCure Medical Ltd (ICCM)
| Market Cap | 70.33M |
| Revenue (ttm) | 2.79M |
| Net Income (ttm) | -15.58M |
| Shares Out | 68.95M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 341,869 |
| Open | 1.030 |
| Previous Close | 1.030 |
| Day's Range | 1.020 - 1.040 |
| 52-Week Range | 0.480 - 1.660 |
| Beta | 2.48 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+96.08%) |
| Earnings Date | Aug 13, 2025 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense s... [Read more]
Financial Performance
In 2024, IceCure Medical's revenue was $3.29 million, an increase of 1.92% compared to the previous year's $3.23 million. Losses were -$15.32 million, 4.55% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ICCM stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
Presentations from 5 Key Opinion Leaders on ProSense® cryoablation including 3 independent studies on breast cancer and 1 on endometriosis 3 hands-on training sessions for doctors interested in usi...
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
The invention is designed to improve cryoprobe extraction, further reducing risk of tissue trauma, leading to lower costs and improved patient experience XSense™ System with Cryoprobes recently receiv...
IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications
Approved for a broad range of indications including in gynecology, oncology and general surgery CAESAREA, Israel , Sept. 15, 2025 /PRNewswire/ -- IceCure Medical Ltd.
Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate
Article published in European Journal of Surgical Oncology focused on cosmetic outcomes and patient satisfaction reports 95% of patients were very satisfied or satisfied with thermal ablation Article ...
IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy
Independent study reports pain scores declined from a median of 8 on a scale of 0-10 to a median of 0 for patients who had ProSense® cryoablation procedures ProSense® is FDA cleared and approved in th...
IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q2 2025 Earnings Conference Call August 13, 2025 10:00 AM ET Company Participants Michael Polyviou - IR, EVC Group Inc. Eyal Shamir - CEO & Director Ronen Tsimerman ...
IceCure Reports Financial & Operational Results for the First Half of 2025
$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Co...
IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025
CAESAREA, Israel , Aug. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
CAESAREA, Israel , July 29, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of...
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
CAESAREA, Israel , July 24, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Announces Commencement of Rights Offering
CAESAREA, Israel , July 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
CAESAREA, Israel , July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Announces Record Date for Rights Offering for Up to $10 Million
CAESAREA, Israel , June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destr...
IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes
IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancer CAESAREA, Israel , June 9, 2025 /PRNews...
IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q1 2025 Earnings Conference Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - IR Eyal Shamir - CEO Ronen Tsimerman - CFO and COO Conference Call ...
IceCure Medical Reports First Quarter 2025 Financial Results
Recently finalized and delivered proposed post market study plan to the FDA; Awaiting marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer Continues...
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
CAESAREA, Israel , May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation
Breast surgeons expressed strong interest in participating in IceCure's planned post-market study for ProSense® in the treatment of early-stage breast cancer ICE3 study named as one of the "Best Paper...
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast sur...
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryo...
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation
Breast cancer cryoablation was a major focus at ECIO 2025 with a dedicated scientific session Independent studies of ProSense® featured in scientific sessions and abstracts including data from the THE...
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Dire...
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical c...
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery CAESAREA, Israel , March 24, 20...